Insights about U.S. Stocks that landed in the Green-Zone during Wednesday’s trade, are depicted underneath:

IsoRay, Inc (NYSEMKT:ISR)’s shares picked up 11.33%, and closed at $1.67.

Formerly on February 18, IsoRay, Inc. (ISR), a medical technology corporation and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, declared its financial results for the quarter and six months ended December 31, 2014. With over $20,000,000 of cash on hand and no debt, IsoRay is positioned to be a dominant player in the brachytherapy cancer treatment market.

IsoRay’s team remains focused in diversifying its product offerings through institutional based studies designed to address various aggressive cancers that to date often fail current standard of care options. Administration is hopeful that the lingering decline in the prostate market may be bottoming out. Administration anticipates seeing modest gains in IsoRay’s market share in addition to some proceed growth in the coming quarters. We practiced a negative influence on our international sales efforts during the quarter ended December 31, 2014, with the devaluation of the Euro causing our products to become higher in price, making it more difficult to attract new adopters in this market.

IsoRay, Inc., through its partner, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which is expanding brachytherapy options throughout the body.

Orexigen Therapeutics, Inc (NASDAQ:OREX), raised 11.13%, and closed at $8.49.

Formerly on February 25, Orexigen Therapeutics, Inc. (OREX), declared business and financial results for the fourth quarter and year ended December 31, 2014.

Contrave (naltrexone HCl / bupropion HCl extended release):

Financial results for the year ended December 31, 2014:

For the year ended December 31, 2014, Orexigen stated a net loss of $37.5 million, or $0.32 per share, as contrast to a net loss of $77.7 million, or $0.80 per share, for 2013. Total operating expenses for 2014 were $86.1 million contrast to $80.6 million for 2013. This overall raise in operating expenses primarily reflects an raise in raw materials, inventory, and manufacturing-related expenses and in stock based compensation expense. The overall raise was partially offset by a decrease in research and development expenses associated with the conduct of the Light Study, the Contrave cardiovascular outcomes trial. While Orexigen is responsible for manufacturing Contrave, Takeda will reimburse Orexigen for manufacturing related costs, counting finished goods.

Orexigen Therapeutics, Inc. is a biopharmaceutical corporation focused on the treatment of obesity. Orexigen developed Contrave® (naltrexone HCl and bupropion HCl extended release), which is approved in the United States and is being commercialized there by the corporation’s North American partner, Takeda Pharmaceuticals. In Europe the drug is being reviewed for marketing authorization under the brand name MysimbaTM (naltrexone HCl/ bupropion HCl prolonged release).

Celldex Therapeutics, Inc (NASDAQ:CLDX), rose 11.11%, and closed at $29.30, hitting new 52-week high of $29.50. The company holds the book value per share of 2.36, whereas cash per share is 2.08. Price to book value is estimated to be 12.42, while price to sale value is 788.17. Analysts mean recommendation for the stock is said to be 1.30 (where 1=Buy, 5=sale).

NeoPhotonics Corp(NYSE:NPTN), enhanced 11.43%, and closed at $3.50.

NeoPhotonics Corporation (NPTN), a leading designer and manufacturer of hybrid photonic integrated optoelectronic modules and subsystems for bandwidth-intensive, high-speed communications networks, declared financial results for its fourth quarter and year ended December 31, 2014.

• Proceed was $79.0 million, a record high fourth quarter, up $4.6 million, or 6.2%, from the fourth quarter of 2013, and a decrease of $2.6 million, or 3.2%, from the preceding quarter.
• Gross margin was 28.7%, up from 26.4% in the fourth quarter of 2013, and up from 24.6% in the preceding quarter.
• Non-GAAP gross margin was 30.3%, up from 27.5% in the fourth quarter of 2013, and up from 26.5% in the preceding quarter.
• Net revenue was $1.6 million, up from a loss of $4.5 million in the fourth quarter of 2013, and up from a loss of $1.9 million in the preceding quarter.

NeoPhotonics is a leading designer and manufacturer of hybrid photonic integrated optoelectronic modules and subsystems for bandwidth-intensive, high-speed communications networks. The Corporation’s products enable cost-effective, high-speed data transmission and efficient allocation of bandwidth over communications networks.